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Abstract
Background: Cases of thrombosis with thrombocytopenia syndrome (TTS) have been reported following vaccination with
AZD1222 or Ad26.COV2.S. This review aimed to explore the pathophysiology, epidemiology, diagnosis, management, and prognosis of TTS.
Methods: A systematic review was conducted to identify evidence on TTS till 4th September 2021. Case reports and series
reporting patient-level data were included. Descriptive statistics were reported and compared across patients with different
sexes, age groups, vaccines, types of thrombosis, and outcomes.
Findings: Sixty-two studies reporting 160 cases were included from 16 countries. Patients were predominantly females with a
median age of 42.50 (22) years. AZD1222 was administered to 140 patients (87·5%). TTS onset occurred in a median of 9 (4)
days after vaccination. Venous thrombosis was most common (61.0%). Most patients developed cerebral venous sinus thrombosis (CVST; 66.3%). CVST was signiﬁcantly more common in female vs male patients (p = 0·001) and in patients aged <45
years vs ≥45 years (p = 0·004). The mortality rate was 36.2%, and patients with suspected TTS, venous thrombosis, CVST, pulmonary embolism, or intraneural complications, patients not managed with non-heparin anticoagulants or IVIG, patients receiving platelet transfusions, and patients requiring intensive care unit admission, mechanical ventilation, or inpatient neurosurgery
were more likely to expire than recover.
Interpretation: These ﬁndings help to understand the pathophysiology of TTS while also recommending diagnostic and management approaches to improve prognosis in patients.
Funding: This research received no speciﬁc grant from any funding agency in the public, commercial, or not-for-proﬁt sectors.
Keywords
COVID-19 vaccines, ChAdOx1 COVID-19 vaccine, Ad26.COV2.S vaccine, thrombosis with thrombocytopenia syndrome,
vaccine-induced immune thrombotic thrombocytopenia

Introduction
Having exerted widespread effects over all spheres of society,
the coronavirus disease 2019 (COVID-19) pandemic has
forced government and healthcare institutions to divert resources and develop methods to curtail it. Vaccines have been put
under extreme emphasis as the prime method of halting transmission, with over one billion doses administered worldwide.
Among these vaccines, the Oxford-AstraZeneca (AZD1222)
and the Johnson & Johnson (Ad26.COV2.S) have recently been
implicated in an extremely rare prothrombotic disorder comprising of thrombosis in uncommon sites with concurrent
thrombocytopenia and development of anti-platelet factor 4
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(anti-PF4) antibodies.1,2 This disorder has been termed as
thrombosis with thrombocytopenia syndrome (TTS).
Owing to its atypical presentations, TTS can present as a
diagnostic challenge for healthcare workers. The common manifestations range from routine constitutional changes to visual
defects, severe headaches, leg and back pains, easy bruising,
or petechiae. Unchecked, TTS may lead to cerebral hemorrhages and fatality.1,3 As reports of TTS came to light, administration of both vaccines was temporarily restricted, with
Denmark and Norway permanently halting the AZD1222
vaccine.
Similar to its rare occurrence, current evidence on TTS is
also limited, existing in the form of case reports and series.
Further hampering this issue, a large proportion of available
data is centered around pharmacovigilance programs, such as
Vaccine Adverse Event Reporting System (VAERS) and
Medicines and Healthcare products Regulatory Agency
(MHRA).4,5 While these systems are excellent at providing
early warnings for pharmacological adverse events, their capacity to inform clinical decision-making is limited, owing to their
reliance on non-standardized patient-reported outcomes.
We conducted a systematic review of patient-level data with
the aim of summarizing the limited data available and explore
the pathogenesis, epidemiology, clinical features, diagnoses,
management, and prognoses in TTS patients.

Methods
The protocol of this review is registered with PROSPERO
CRD42021252688, and this review has been reported in accordance with the Preferred Reporting Items for Systematic
Reviews and Meta-Analysis (PRISMA) guidelines.

Electronic Searches
An exhaustive literature search was conducted on PubMed,
Embase, CINAHL, Scopus, LILACS, Global Index Medicus,
World Health Organization (WHO) COVID-19 Database,
Europe PMC, ScienceDirect, Preprints, medRxiv, Open
Science Framework (OSF), and Research Square to identify
all scientiﬁc literature available till 4th September 2021. No language restrictions were applied. The strategies employed for
searching these databases are documented in Supplementary
Appendix (p3-7).
In addition, reference lists of all identiﬁed review articles and
included studies were checked for additional references. To
identify potentially relevant gray literature, reports and guidelines published by several hematological and pharmacovigilance organizations were hand searched (appendix p8).

Selection Strategy
Case reports and series providing patient-level data on TTS
cases were included in this review. Patients with radiologically
conﬁrmed venous or arterial thrombosis and associated thrombocytopenia (platelet count <150 000/mm3) occurring within 4
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to 30 days of administration of AZD1222 or Ad26.COV2.S
vaccine were classiﬁed as conﬁrmed TTS cases if their enzymelinked immunosorbent assay (ELISA) heparin-PF4 antibodies
were positive.3 Patients meeting the above criteria but with
missing ELISA results were considered suspected cases.
EndNote x9 by Clarivate Analytics was used to remove
duplicate records. Title and abstracts of deduplicated records
were screened by UW and SA independently using Rayyan
QCRI.6 Full-text review was independently performed by
MST and AH. All discrepancies were resolved through discussion and consensus.

Data Extraction
Data extraction from the included studies was performed by
SMG, MST, ZA, and AH using a structured Microsoft Excel
2016 worksheet. The worksheet was piloted prior to data
extraction on two studies randomly selected from the included
studies.
The extracted variables included: study characteristics (country,
setting, type); patient demographics (age, sex, ethnicity, comorbidities, current medications, SARS-CoV-2 infection status,
SARS-CoV-2 serology, vaccine administered, number of doses
administered); clinical manifestations (time of onset of TTS after vaccination, presenting signs and symptoms); radiological characteristics
(imaging modalities, venous/arterial thrombosis, blood vessel(s)
involved); laboratory parameters (platelet count, hemoglobin, leukocytes, ﬁbrinogen, aspartate aminotransferase (AST), alanine aminotransferase (ALT), γ-glutamyltransferase (GGT), lactate
dehydrogenase (LDH), serum creatinine, lactate, C-reactive protein,
D-dimers, activated partial thromboplastin time (APTT), prothrombin time (PT), thrombin time (TT), international normalized ratio
(INR), blood ﬁlm, antiphospholipid antibodies, anti-PF4 antibodies);
therapeutic management (heparin, steroids, intravenous immunoglobulins (IVIGs), platelet transfusions, non-heparin anticoagulants,
thrombectomy, intensive care unit (ICU) admission, mechanical ventilation); and outcomes (complications, recovery, mortality).
Comorbidities, current medications, SARS-CoV-2 infection
status, recent exposure to heparin prior to TTS onset, and complications were assumed negative unless otherwise speciﬁed in
included studies. However, these characteristics were marked
unknown when studies reported aggregated data and it was not
possible to disaggregate data to individual patients.
Management options were marked unknown for studies reporting aggregated data and for studies not documenting at least
one of the following management options: heparin, steroids,
intravenous immunoglobulins (IVIGs), platelet transfusions,
and non-heparin anticoagulants. For remaining studies, management options were assumed negative unless otherwise speciﬁed.
TTS onset was deﬁned as the time of the ﬁrst symptom
occurring on or after the fourth day of vaccination. For all laboratory parameters, we extracted the ﬁrst-available and most
abnormal results. Severe thrombocytopenia was deﬁned as a
platelet count ≤25 000/mm3. The ﬁnal dataset was rechecked
thrice for accuracy by SMG, MST, and ZA by referring to original studies, and all discrepancies were resolved accordingly.
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Statistical Analyses

Patient Demographics

Analyses were performed on IBM SPSS Statistics version 24.
Descriptive statistics were reported. Shapiro-Wilk tests for normality were performed to assess the distributions of continuous
variables (Table S1, appendix p9-10), and they were presented
as means ± standard deviations or medians (interquartile ranges
[IQRs]) as appropriate. Categorical variables were summarized
using frequencies and percentages.
Clinicodemographic characteristics were compared across
patients with different sexes, age groups, vaccines, types of
thrombosis, and outcomes. For these comparisons, continuous
variables, such as age, days from vaccination to TTS onset,
and days from vaccination to hospitalization, were converted
to categorical variables. These comparisons were performed
using chi-squared tests or Fisher’s exact tests, when assumptions for the former were not met. Missing data were included
in analyses, allowing denominators to remain consistent. For
sensitivity analyses, clinicodemographic characteristics were
compared across patients with different outcomes after excluding suspected TTS cases. All analyses were two-sided with p
<0·05 considered threshold for statistical signiﬁcance.

From the included studies, 160 patients (120 conﬁrmed and 40
suspected) were included in this review after excluding 21 ineligible patients (Table S4, appendix p29). The patients were
predominantly females with a median age of 42·50 years
(IQR 22, range 21–77 years; N = 132). Most patients were
from the United Kingdom and France (28·1% [45 of 160]
and 16·9% [27 of 160], respectively). Ethnicity was documented for only 29 patients, out of which, 26 were
Caucasians and 3 Asians.
At the time of vaccination, most patients had insigniﬁcant
preexisting comorbidities, active medications, exposure to
heparin, and pregnancy status. Only two patients (1.3% [2 of
160] had documented history of prior SARS-CoV-2 infection,
while another patient (0·6% [1 of 160]) had COVID-19 at presentation. COVID-19 serology was positive in 38 of 59 patients
(64·4%), with all patients developing antibodies against the
spike glycoprotein (Table 2). Among patients who had received
Ad26.COV2.S vaccine, COVID-19 serology was insigniﬁcant
in 5 (100% [5 of 5]) and unknown in the remaining 15 patients
(Table S6; appendix p33–35).

Quality Assessment

Clinical Manifestations

Quality assessment of included studies was independently conducted by UW and SA using the National Institute of Health
Quality Assessment Tool for Case Series Studies.7 Each case
series was scored out of nine, based on clarity of study objectives, case deﬁnition, consecutive subject recruitment, comparability of subjects, clarity of intervention, deﬁnition and
measurement of outcomes, length of follow-up, statistical
methods, and results. A case series scoring seven to nine was
considered good quality, four to six fair considered quality,
and less than four considered poor quality. Consecutive
subject recruitment, comparability of subjects, and statistical
methods were excluded from the scoring criteria for case
reports, which were consequently scored out of six. Case
reports scoring six were considered good quality, three to ﬁve
considered fair quality, and less than three considered poor
quality.

A total of 140 of 160 patients (87·5%) were administered
AZD1222 while the rest had received Ad26.COV2.S vaccine.
For patients receiving AZD1222 vaccine, onset of TTS predominantly occurred after the ﬁrst dose (76/77, 98.7%), while
dosages were unknown for the remaining 63 patients. The
median number of days from vaccination to TTS onset and hospitalization were 9 (4; N = 131) and 11 (5; N = 113), respectively. Patients who were hospitalized within 15 days of
vaccination were more likely to have received AZD1222
vaccine than Ad26.COV2.S vaccine (p <0.0010); Table S6,
appendix p33–35). Patients had a median length of hospital
stay of 7 (11; N = 40) days.
Venous thrombosis was most common among patients, followed by combined arterial and venous thrombosis and isolated
arterial thrombosis. Most patients developed cerebral venous
sinus thrombosis (CVST), predominantly affecting the transverse, sigmoid, and sagittal sinuses. CVST was signiﬁcantly
more common in in female vs male patients (p = 0·001;
Table S7, p36–38) and in patients aged <45 years vs ≥45
years (p = 0·004; Table S8, p39-41). Splanchnic vein thrombosis (SVT) and pulmonary embolism (PE) were also documented
in a subset of patients. Other relatively common locations of
thrombosis were deep veins, internal jugular vein, and portal
vein (14·4% [23 of 160], 11·3% [18 of 160], and 10.6% [17
of 160]], respectively).
Presenting symptoms commonly included severe headache
or neurologic changes in patients with CVST; abdominal
pain or backache in patients with SVT; chest pain or shortness
of breath in patients with PE; and leg pain or swelling in
patients with deep vein thrombosis (DVT). Symptoms of
thrombocytopenia, such as petechiae or mucosal bleeding,

Results
The literature search yielded 36 734 studies after deduplication
(Figure 1). Out of these, 92 studies were reviewed as full text
and 62 studies were included according to our inclusion criteria
(Table S2, appendix p11-26).1,2,8-67 The remaining 30 studies
were excluded (Table S3, appendix p27-28).
Among the included studies, 21 studies were case series
while 41 were case reports. Most studies were published at
the time of reporting of this review, except for three which
were preprints.14,23,28 Majority of the studies (N = 59) originated from high-income countries (HICs), with most being
reported from United Kingdom (Table 1).
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Figure 1. PRISMA ﬂow diagram of study selection process

were often present as well. Computed tomography (CT), magnetic resonance imaging (MRI), ultrasound, and digital subtraction angiography were the most common imaging
modalities employed to visualize thrombosis and associated
complications.

Laboratory Parameters
ELISA for PF4 antibodies was positive in 120 patients (100%
[120 of 120]), while 15.6% patients (25 of 160) were tested
with unspeciﬁed assays and 5·6% patients (9 of 160) were not
tested for anti-PF4 antibodies. Serotonin release assays
(SRAs) were used in six conﬁrmed patients and yielded positive
results. Among the rapid HIT assays, chemiluminescence

immunoassays (CLIAs) were negative in four conﬁrmed
patients, latex-enhanced immunoassays negative in three conﬁrmed and two suspected patients, and lateral ﬂow immunoassays negative in one conﬁrmed and one suspected patient.
All patients had a signiﬁcant decline in platelet count at diagnosis, but the exact platelet counts were missing for 28 patients.
Among the remaining patients, 45.5% (60 of 132]) developed
severe thrombocytopenia. Additionally, many patients had elevated levels of D-dimers, PT, TT, and INR with low levels of
ﬁbrinogen. Blood ﬁlms results were documented for 12 of
160 patients (7.5%), revealing schistocytes and platelet anisocytosis in 16.7% patients each (2 of 12). Antiphospholipid antibodies were assessed in 71 (44·4% [71 of 160]) and were
positive in 4 patients (5·6% [4 of 71]).
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Table 1. Distribution of studies (N = 62) and TTS cases (N = 160)
according to country of origin

Country
Austria
Austria &
Germany
Canada
Denmark
France
Germany
India
Italy
Norway
Oman
Republic of
Korea
Republic of
North
Macedonia
Saudi Arabia
Slovenia
Taiwan
United
Kingdom
(UK)
United States of
America
(USA)

World Bank country
classiﬁcation by
income level

Number of
studies
(N = 62)

Number of
TTS cases
(N = 160)

HIC
HICs

3 (4·84%)
1 (1·61%)

4 (2·50%)
10 (6·30%)

HIC
HIC
HIC
HIC
LMIC
HIC
HIC
HIC
HIC

2 (3·23%)
2 (3·23%)
7 (11·29%)
7 (11·29%)
2 (3·23%)
8 (12·90%)
3 (4·84%)
2 (3·23%)
1 (1·61%)

3 (1·90%)
2 (1·30%)
27 (16·90%)
19 (11·90%)
2 (1.30%)
9 (5·60%)
11 (6·90%)
2 (1.30%)
1 (0.60%)

UMIC

1 (1·61%)

1 (0.60%)

HIC
HIC
HIC
HIC

1 (1·61%)
1 (1·61%)
2 (3·23%)
10
(16·13%)

1 (0.60%)
1 (0.60%)
2 (1.30%)
45 (28·10%)

HIC

9 (14·52%)

20 (12·50%)

HIC: high-income country; UMIC: upper-middle-income country; LMIC:
lower-middle-income country; LIC: low-income country; TTS: thrombosis with
thrombocytopenia syndrome

Other intraneural complications commonly included brain
herniation (18 of 160 patients, 11·3%) and cerebral edema (11
of 160 patients, 6.9%). These complications were signiﬁcantly
more common in patients who were administered AZD1222
vaccine vs Ad26.COV2.S vaccine (p = 0·046; Table S6, appendix p33-35).
Extra-neural complications were relatively uncommon, primarily manifesting as edema, ischemia, or infarction of the
bowel wall, cardiac arrest, myocardial infarction, severe acute
respiratory syndrome, or toe infarction. The incidence of extraneural complications was higher in patients with combined arterial
and venous thrombosis vs isolated arterial or venous thrombosis
(p = 0·017; Table S9, appendix p42-44).
The mortality rate in this review was 36·2% (47 of 130),
while outcomes were unknown for 30 patients. Compared to
recovery, mortality was more common among suspected TTS
patients, patients with venous thrombosis, CVST, pulmonary
embolism, or intraneural complications, patients not managed
with non-heparin anticoagulants or IVIG, patients receiving
platelet transfusions, and patients requiring ICU admission,
mechanical ventilation, or neurosurgery (Table S10, appendix
p45-47).
On sensitivity analysis, treatment with IVIG was not signiﬁcantly associated with mortality or recovery. Additionally, mortality was found to be more common compared to recovery in
patients receiving oral contraceptives (p = 0·0090) and those
developing intracranial hemorrhages (p = 0.0080). The validity
of other ﬁndings remained unchanged (Table S11, appendix
p48-50).

Quality Assessment of Included Studies
Therapeutic Management
Heparin was administered to 35 patients (37.2% [35 of 94]),
with majority receiving low-molecular-weight-heparins
(LMWHs). Most patients were administered steroids, IVIG,
and non-heparin anticoagulants. A subset of patients was also
managed with platelet transfusions, endovascular thrombectomy, ICU admission, and mechanical ventilation.

Complications and Outcomes
A signiﬁcant proportion of patients developed hemorrhages (60
of 160 patients, 37·5%), with intracranial hemorrhages being
more common than extracranial hemorrhages. Subtypes of
intracranial hemorrhage included intracerebral (56.8% patients
[21 of 37]), subarachnoid (32.4% [12 of 37]), combined intracerebral and subdural (2.7% [1 of 37]), and combined intracerebral and subarachnoid hemorrhages (8.1% [3 of 37]). Subtypes
of intracranial hemorrhage were unknown for 21 patients.
Extracranial hemorrhages involved the gastrointestinal system
(GIT), adrenal glands, conjunctiva, and surgical site (33·3%
[2 of 6], 33·3% [2 of 6], 16·7% [1 of 6], and 16·7% [1 of 6]
patients, respectively).

A total of 37 studies were determined to be of good quality while
the remaining 25 studies were of fair quality (Table S5, appendix
p30-32). Studies were primarily downgraded for unclear study
population,9,10,12,15,16,20,25,26,35,37,38,42,45,46,50-53,57-59,62,64-66 nonconsecutive subject recruitment,1,2,8,9,11,20-23,28,29,31,35,37,65,67
incomparable subjects,20,35,37 unclear intervention,2,8,9,16,21,22
inadequate length of follow-up,1,2,9,19,22,28,32,67 inadequate
description of statistical methods,20,35,42 and inadequate description of results.20 Common causes for downgrading studies were
unclear study population and non-consecutive subject recruitment, raising concerns that the included sample could be biased
towards severer presentations.

Discussion
Manifesting with atypical thrombosis, thrombocytopenia,
and anti-PF4 antibodies, TTS is an extremely rare but
serious platelet-activating prothrombotic disorder that clinically resembles spontaneous HIT.68-70 The concurrence of
thrombosis and thrombocytopenia in TTS indicates an
immunological etiology contributing to the hypercoagulable
state.71 In the case of HIT, the prothrombotic state has been
associated with IgG-speciﬁc antibodies, capable of recognizing multimolecular complexes between the cationic PF4
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Table 2. Clinicodemographic characteristics of all patients (N = 160)

Table 2. (continued)

Variable

Variable

Sex
Male
Female
Unknown
Age/years
29 or less
30–49
50–69
70 or more
Unknown
Comorbidities
Hematological
Other
None
Unknown
Medications
Contraception
Other
None
Unknown
COVID-19 serology
Antibodies against spike protein
Antibodies against nucleocapsid
Antibodies against both
No antibodies
Unknown
Vaccine
AZD1222
Ad26.COV2.S
TTS
Conﬁrmed
Suspected
Days from vaccination to TTS onset
6 or less
7–8
9–10
11–12
13 or more
Unknown
Days from vaccination to hospitalization
9 or less
10–11
12–13
14–15
16 or more
Unknown
Thrombosis
Arterial
Venous
Both
Unknown
CVST
Splanchnic vein thrombosis
Pulmonary embolism
Management: Heparin
Yes
No
Unknown

Frequency (%)
48 (32·2%)
101 (67·8%)
11
24 (17·5%)
66 (48·2%)
42 (30·7%)
5 (3·6%)
23
3 (2·4%)
36 (28·3%)
88 (66·3%)
33
9 (7·7%)
10 (8·5%)
98 (83·8%)
43
38 (64·4%)
0 (0·0%)
0 (0·0%)
21 (35·6%)
101
140 (87·5%)
20 (12·5%)
120 (75·0%)
40 (25·0%)
15 (11·5%)
45 (34·4%)
25 (19·1%)
21 (16·0%)
25 (19·1%)
29
28 (24·8%)
32 (28·3%)
19 (16·8%)
12 (10·6%)
22 (19·5%)
47
20 (12·6%)
97 (61·0%)
42 (26·4%)
1
106 (66·3%)
39 (24·4%)
48 (30·0%)
35 (37·2%)
59 (62·8%)
66
(continued)

Management: Heparin subtypes
Unfractionated
LMWH
Both
Class unknown
Management: Non-heparin anticoagulants
Yes
No
Unknown
Management: Steroids
Yes
No
Unknown
Management: IVIG
Yes
No
Unknown
Management: Platelet transfusions
Yes
No
Unknown
Management: Thrombectomy
Yes
No
Unknown
ICU admission
Yes
No
Unknown
Mechanical ventilation
Yes
No
Unknown
Hemorrhage
Intracranial
Extracranial
Both
None
Other intraneural complications
Extra-neural complications
Craniectomy/hemicraniectomy
Outcome
Recovering
Mortality
Unknown

Frequency (%)
6 (20·7%)
21 (72·4%)
2 (6·9%)
6
62 (64·6%)
34 (35·4%)
64
48 (50·0%)
48 (50·0%)
64
62 (64·6%)
34 (35·4%)
64
21 (21·9%)
75 (78·1%)
64
14 (14·6%)
82 (85·4%)
64
26 (26·5%)
72 (73·5%)
62
16 (16·3%)
82 (83·7%)
62
53 (33·1%)
3 (1·9%)
4 (2·5%)
100 (62·5%)
38 (23·8%)
23 (14·4%)
25 (15·6%)
83 (63·8%)
47 (36·2%)
30

TTS: thrombosis with thrombocytopenia syndrome; CVST: cerebral venous
sinus thrombosis; LMWH: low-molecular-weight-heparin; IVIG: intravenous
immunoglobulin; ICU: intensive care unit

and the anionic heparin.69 However, the unique aspect of
TTS is that there is no prior exposure to heparin that can
explain the subsequent development of thrombosis and
thrombocytopenia. While existing theories have proposed
that one or more anionic components of the vaccines could
be triggering the formation of anti-PF4 antibodies, the
exact pathophysiology of TTS remains an active area of
investigation globally. 1
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Implicated in the development of TTS, AZD1222 and
Ad26.COV2.S are adenoviral vector-based vaccines encoding
the spike glycoprotein. Our review identiﬁed more cases of
TTS patients who were administered AZD1222 compared to
patients who received Ad26.COV2.S. While the exact reason
for this pattern is unknown, we propose several hypotheses
that could explain this difference.
First, AZD1222 uses a chimpanzee vector while
Ad26.COV2.S utilizes the human Ad26-based vector, engaging
different host cell receptors. Additionally, Ad26.COV2.S
vaccine transgene encodes for a membrane-bound
SARS-CoV-2 spike glycoprotein that does not shed S1,
which is substantially different from the unmodiﬁed spike glycoprotein coded by AZD1222. These differences can lead to
different phylogenetic and biological characteristics, potentially
resulting in different vaccine safety with regards to TTS.72
However, another adenoviral vaccine, Sputnik V, also utilizes
the human Ad26 serotype along with Ad5 serotype in two separate doses,73 and despite being administered in multiple countries, there are no reported cases of TTS following vaccination
with Sputnik V till date.74
Second, TTS is an extremely rare disorder with an incidence
rate ranging from 1 in 125 000–1,000,000 individuals vaccinated for SARS-CoV-2.75 Across 31 countries with data available, AZD1222 has been administered to approximately 48
million individuals compared to 19 million who received
Ad26.COV2.S till 25th June 2021.76 Additionally, both vaccines are being administered in different parts of the world,
with AZD1222 being more common in Europe and
Ad26.COV2.S being more common in the United States.
Pharmacovigilance capacities differ signiﬁcantly between
Europe and the United States, which could potentially lead to
differences in reporting of TTS.77 Regardless, these hypotheses
cannot be conﬁrmed in the absence of reliable epidemiological
data originating from high-quality and uniform pharmacovigilance systems.
In our review, a majority of TTS patients were females, those
aged 30–49 years, and those without any known comorbidities.
These gendered trends could be attributed to the clinical and
pathophysiological resemblance of TTS with HIT, considering
that females have twice the risk of developing HIT compared to
males.78 Existing theories explaining these trends in HIT are
based upon sex-dependent immune responses to heparin-PF4
multimolecular complexes.78 However, the extent to which
these theories can be extrapolated to TTS is currently
unknown, owing to the absence of heparin exposure in TTS
patients. On the other hand, TTS patients in our review exhibited contradictory age trends compared to HIT, which is rare in
patients aged <40 and has a higher incidence in older patients.79
Among all patients, venous thrombi were more common
compared to arterial thrombi, another feature that TTS shares
with HIT.80 However, while statistically insigniﬁcant, male
patients more often developed arterial thrombosis compared
to female patients in this review. Generally, risk factors contributing to stasis and hypercoagulability components of the
Virchow’s triad are most signiﬁcant for venous thrombosis,
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while those contributing to vessel wall changes relatively
stand out more in arterial thrombosis.81 Most of the female
patients included in this review were 21–49 years of age, and
hence, are expected to have protective effects of estrogen on
blood vessel walls.82
Additionally, existing literature had hypothesized that, compared to younger patients, older TTS patients might be more
likely to present with arterial thrombosis.83 This could be attributed to the post-menopausal loss of protective effects of estrogen, considering that most patients with TTS were females. Our
review also identiﬁed the incidence of arterial thrombosis to be
higher in patients aged ≥45 vs <45 years, but this difference
was not statistically signiﬁcant.
When compared with HIT, another contradictory characteristic of TTS is that a majority of patients develop CVST more so
than elsewhere in the body, as highlighted in our review. On the
other hand, CVST is extremely rare in patients with HIT, with
very limited number of cases documented in literature.84
While the pathophysiology of CVST in the setting of TTS warrants further investigations, our ﬁndings indicate that CVST is
signiﬁcantly more common in female patients and patients
aged <45 years. Intracranial hemorrhages have traditionally
been common in CVST patients, developing in nearly
one-third of cases.85 This can explain the high proportion of
TTS patients with intracranial hemorrhages observed in our
review.
For diagnostic purposes, existing guidelines recommend
testing suspected TTS patients for anti-PF4 antibodies prior
to initiation of therapy, particularly using the ELISA assay.3
Individuals with TTS often have high optical density (OD)
readings, ranging from 2·00 to 3·00 or even higher, which
are sufﬁcient to inform diagnosis in the setting of thrombosis
and thrombocytopenia following recent COVID-19 vaccination without any exposure to heparin.1,31 Despite being the
gold-standard for diagnosing HIT, SRAs are often not
required in suspected TTS patients with strongly positive
ELISA results, with our review only identifying six patients
tested with SRAs. This can be attributed to the higher cost,
turnaround time, and resource intensiveness associated with
SRAs, limiting their use in most settings around the globe.86
While the sensitivity and speciﬁcity of SRAs and ELISA
have not been compared in TTS patients, evidence extrapolated from HIT suggests that SRAs, however, could potentially be helpful in patients with negative or equivocal
ELISA ﬁndings but strong suspicion of TTS, owing to their
greater speciﬁcity in HIT.87 However, this necessitates
further investigations, considering that patients with negative
ELISA results were excluded from this review.
We recommend that rapid HIT assays, such as CLIAs, latexenhanced immunoassays, and lateral ﬂow immunoassays,
should not be used to conﬁrm or exclude diagnosis of TTS.
While these assays can provide rapid results with credible diagnostic accuracy in the case of HIT,88 they were consistently
negative in TTS patients included in this review.
Physicians suspecting TTS should have a lower threshold for
conducting diagnostic investigations, including complete blood
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count and imaging based on presenting symptoms. Upon detection of thrombocytopenia and thrombosis, ELISA, D-dimers,
ﬁbrinogen, PT, and APTT should be immediately requested
to conﬁrm the diagnosis. In our review, suspected patients
who were not tested with ELISA were more likely to expire
than recover, highlighting the signiﬁcance of early diagnostic
investigations and subsequent treatment initiation.
In this review, unfractionated heparins were less commonly
administered to patients compared to LMWHs. Because of
inadequate sample size, we cannot conclusively comment on
the safety of either of these in TTS patients. However,
LMWHs might be safer considering that they have smaller
sizes which limit their interaction with PF4 and platelets, translating into a lower risk of immune sensitization and subsequent
development of HIT.89,90 If immune sensitization still occurs,
the antibodies generated by LMWHs belong to the IgA and
IgM classes, which are less associated with development of
HIT, as opposed to the IgG antibodies generated by unfractionated heparins.90
Non-heparin anticoagulants, such as argatroban, danaparoid,
fondaparinux, or direct oral anticoagulants, remain a better
alternative to heparin for TTS patients, considering that they
are not associated with HIT and that patients not managed
with non-heparin anticoagulants were more likely to expire
than recover in our review. IVIG should also be used in conjunction with non-heparin anticoagulants, owing to its success
in the treatment of spontaneous HIT.91,92 We also recommend
avoiding platelet transfusions due to their potential of exacerbating the thrombotic symptoms. Our review identiﬁed a
higher likelihood of mortality compared to recovery among
patients receiving platelet transfusions.
While this review attempts to build upon the gaps in existing
literature, more investigations are still required to completely
understand the pathophysiological elements of TTS, considering
that most existing theories have been extrapolated from evidence
based on HIT. Additionally, despite the suggestive temporal relationship of AZD1222 or Ad26.COV2.S with TTS, caution is
required when drawing conclusions about the safety of these vaccines. TTS is an extremely rare disorder, and the unexpected risk
of TTS following vaccination is insubstantial compared to the
risk of developing COVID-19 without vaccination.3
This review has several limitations which need to be
accounted for while interpreting our results. First, since TTS
is an extremely rare disorder, we could only identify 160
patients, and those too with a lot of missing data, impacting
the quality of our analyses. Second, some laboratory assessments were not conducted in a signiﬁcant number of patients.
Third, we included case reports and case series in this review,
each of which might have separate confounders which could
not be addressed due to reporting inconsistencies. Regardless
of these limitations, however, this is the largest review on
TTS reported till date.
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